ArticleObesity pillars2026
Genetic variants of the leptin-melanocortin pathway in a clinically selected Greek cohort with severe early-onset obesity and hyperphagia: implications for precision obesity medicine.
Article in Obesity pillars, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rare genetic forms of obesity are characterized by severe, early-onset obesity and hyperphagia, often involving the leptin-melanocortin pathway. Although advances in genetic testing have improved the recognition of monogenic obesity, data from Southern European populations remain limited. We investigated the genetic landscape and associated clinical characteristics of Greek patients with severe early-onset obesity and hyperphagia. Methods: This retrospective, single-center, observational study included 67 children and adults with severe obesity and hyperphagia, consecutively recruited at the University Hospital of Patras, Greece, between September 2019 and November 2020. Targeted next-generation sequencing, supplemented by Sanger sequencing, evaluated 101 genes associated with monogenic obesity. Variants were classified according to the American College of Medical Genetics and Genomics (ACMG) criteria. Results: Among 67 participants, 37 (55.2%) carried obesity-associated variants, with 51 variant findings identified across 24 genes, predominantly involving Conclusion: Genetic variants affecting the leptin-melanocortin pathway were frequently identified in this cohort of patients, highlighting the marked genetic heterogeneity of rare obesity. From a clinical perspective, these findings support phenotype-driven genetic evaluation in patients with severe early-onset obesity and marked hyperphagia, particularly when syndromic, endocrine, developmental, or behavioral features are present. Genetic results may help establish an etiologic diagnosis, inform genetic counselling and family evaluation, and identify selected patients who may be candidates for mechanism-based therapies. Because most detected variants were VUS, results should be interpreted by clinicians with expertise in obesity and genetics and should not be used to guide treatment on the basis of a VUS alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.